Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...
The FDA has granted Orphan Drug designation to ATX01 (proprietary topical amitriptyline; AlgoTherapeutix) for the treatment of erythromelalgia. The Food and Drug Administration (FDA) has granted ...
The global erythromelalgia treatment market reach USD 1.98 Billion in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2032 PUNE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results